PTPN3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13736685	1.00	2/20
SCHEMBL15829189	1.00	2/20
SCHEMBL18230879	0.81	2/20
SCHEMBL15829194	0.80	2/20
SCHEMBL15829188	0.78	2/20
SCHEMBL15829190	0.78	2/20
SCHEMBL15829193	0.77	2/20
SCHEMBL18230880	0.76	2/20
SCHEMBL15829191	0.75	2/20
SCHEMBL15829185	0.67	2/20
SCHEMBL18230877	0.67	2/20
SCHEMBL18231230	0.66	2/20
SCHEMBL15829192	0.65	2/20
SCHEMBL15829168	0.65	2/20
SCHEMBL15829166	0.62	2/20
SCHEMBL15829167	0.60	2/20
SCHEMBL15829187	0.59	2/20
SCHEMBL15829172	0.58	2/20
SCHEMBL15829183	0.57	2/20
SCHEMBL15829184	0.53	2/20

Clinical trials — most relevant to PTPN3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance	PHASE4	COMPLETED
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease	nan	NOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?	nan	COMPLETED
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN3 binder may also engage these)

Protein	Name	Similarity
A2ALK8	—	1.000	A2ALK8 →
P70600	—	0.992	P70600 →
F8VPU2	—	0.990	F8VPU2 →
PTK2B	Protein-tyrosine kinase 2-beta	0.989	landscape →
Q8WY64	—	0.988	Q8WY64 →
F1P065	—	0.987	F1P065 →
Q8CHG7	—	0.986	Q8CHG7 →
O94887	—	0.986	O94887 →
Q9QVP9	—	0.986	Q9QVP9 →
Q05AK5	—	0.986	Q05AK5 →
Q9Y4G8	—	0.986	Q9Y4G8 →
Q60695	—	0.986	Q60695 →
F1LYQ8	—	0.986	F1LYQ8 →
Q60629	—	0.986	Q60629 →
F1M386	—	0.985	F1M386 →
Q5RAB8	—	0.985	Q5RAB8 →
P34152	—	0.985	P34152 →
F1PBJ0	—	0.985	F1PBJ0 →
Q4KWH8	—	0.985	Q4KWH8 →
Q9QYJ2	—	0.984	Q9QYJ2 →
Q6AYC5	—	0.984	Q6AYC5 →
Q91ZY8	—	0.984	Q91ZY8 →
O35346	—	0.984	O35346 →
Q9Y4F1	—	0.984	Q9Y4F1 →
Q9NZL6	—	0.984	Q9NZL6 →
Q9MYU8	—	0.984	Q9MYU8 →
P97874	—	0.984	P97874 →
P28191	—	0.984	P28191 →
Q96JB8	—	0.983	Q96JB8 →
Q8N9S9	—	0.983	Q8N9S9 →